Abstract
Regulatory agencies believe microarray data could be extremely useful in testing
prospective chemical products and investigating safety problems after chemicals
have been marketed. However, it has not yet been clearly established how this
information will be used by agencies in the approval of pharmaceuticals and
other chemicals--or even whether companies will be required to submit microarray
data. Although some private companies are already voluntarily submitting microarray
data along with their drug and pesticide applications, others are hesitant
to do so. Most of the stakeholders involved agree that standardization of microarray
experiment procedures and of genomic signatures are key to the broad acceptance
and use of these data.
|